Jail telemedicine study aims to keep opioid patients on track after release
NCT ID NCT07524738
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a long-acting buprenorphine shot (BRIXADI) via telemedicine to 30 jailed adults with opioid use disorder helps them stay on treatment after release. Participants switch from daily pills to weekly or monthly shots before leaving jail, then continue care in the community. The goal is to see if this approach improves medication adherence and reduces opioid use and overdose risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Allegany County Detention Center
Cumberland, Maryland, 21502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tool better measure opioid withdrawal?
- Giving patients a voice in methadone care: a new approach under the microscope
- Can a sleep pill boost success in opioid treatment?
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Could a trip to the pediatrician help teens beat opioid addiction?
- A nose spray before treatment: could naloxone speed up opioid recovery for fentanyl users?